CD274 and neoplasm: Therapy studies with a low PD-L1-expressing cell line in mice (approx. 20% PD-L1 expression in the tumor) showed that a combination therapy (131I-PD-L1 mAb and, 96 h later, anti-PD-L1 mAb) could suppress the tumor growth drastically over 30 days (approx. 600 mm3) compared to the [131I]I-PD-L1 mAb-only therapy (approx. 1000 mm3) and the anti-PD-L1 mAb-only therapy (approx. 2100 mm3).